Exome Asset Management LLC Buys Shares of 45,600 Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Exome Asset Management LLC purchased a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 45,600 shares of the company’s stock, valued at approximately $1,500,000. Exome Asset Management LLC owned 0.12% of Tarsus Pharmaceuticals at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in TARS. Jennison Associates LLC increased its position in Tarsus Pharmaceuticals by 47.2% in the 3rd quarter. Jennison Associates LLC now owns 2,178,580 shares of the company’s stock valued at $71,653,000 after acquiring an additional 698,712 shares during the period. Millennium Management LLC raised its stake in shares of Tarsus Pharmaceuticals by 1,259.3% during the second quarter. Millennium Management LLC now owns 348,586 shares of the company’s stock valued at $9,475,000 after purchasing an additional 322,942 shares in the last quarter. Ally Bridge Group NY LLC acquired a new stake in Tarsus Pharmaceuticals in the third quarter worth about $10,587,000. Vestal Point Capital LP bought a new position in Tarsus Pharmaceuticals in the 3rd quarter valued at about $7,565,000. Finally, Ikarian Capital LLC increased its stake in Tarsus Pharmaceuticals by 28.7% during the 3rd quarter. Ikarian Capital LLC now owns 1,030,277 shares of the company’s stock valued at $33,886,000 after buying an additional 230,000 shares during the period. Institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Price Performance

TARS opened at $52.50 on Friday. The firm has a market capitalization of $2.01 billion, a P/E ratio of -13.78 and a beta of 1.04. The stock has a fifty day moving average of $44.72 and a 200-day moving average of $34.38. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30. Tarsus Pharmaceuticals, Inc. has a 12-month low of $18.30 and a 12-month high of $54.44.

Analyst Ratings Changes

A number of research analysts recently commented on TARS shares. Oppenheimer raised their price objective on shares of Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the company an “outperform” rating in a research note on Thursday, November 14th. The Goldman Sachs Group boosted their price objective on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a research note on Friday, November 15th. Finally, William Blair raised Tarsus Pharmaceuticals to a “strong-buy” rating in a research note on Friday, August 30th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $54.20.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.